Thomas John Charles sold $347K of KRYS
Thomas John Charles (EVP, General Counsel) sold 1,000 shares of Krystal Biotech, Inc. (KRYS) at $347.27 ($0.35M total) on 2026-06-25 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific open-market sale size, price, and post-transaction holdings (0 shares) under a pre-arranged 10b5-1 plan.
Market read
Traders may note insider selling, but the pre-arranged nature and lack of fundamental updates make it low-signal for price action.
What to watch
The filing provides no reason for the sale, and 10b5-1 plans are designed to reduce timing-based inference; transaction size is modest relative to typical institutional flows.
Background
The article is an SEC Form 4 insider transaction disclosure for Krystal Biotech, Inc.
Ticker impact
Krystal Biotech disclosed an EVP/general counsel open-market sale of 1,000 shares at $347.27 on a 10b5-1 plan, leaving 0 shares.
Likely minimal near-term impact; any effect would be limited to short-lived sentiment around insider selling.
Form 4 details a small, pre-planned open-market transaction by a senior officer with no accompanying company-specific news (no guidance, deal, or regulatory action).
Market effects
No clear read-through to biotech/biopharma sector fundamentals from a single, small 10b5-1 sale.
No material regional market implications indicated.
No global catalyst or cross-border transaction described.
Counterpoint
Even with a 10b5-1 plan, the officer ending with 0 shares could be interpreted by some traders as a stronger-than-usual de-risking signal.
Key entities
- issuerKrystal Biotech, Inc.
Subject of the Form 4 insider transaction disclosure (EVP/general counsel sale).
- insiderThomas John Charles
EVP, General Counsel who sold 1,000 shares at $347.27 under a 10b5-1 plan.
